Celon Pharma S.A. (WSE:CLN)

Poland flag Poland · Delayed Price · Currency is PLN
26.20
-0.50 (-1.87%)
Apr 2, 2025, 4:45 PM CET
73.28%
Market Cap 1.42B
Revenue (ttm) 209.54M
Net Income (ttm) 18.51M
Shares Out 53.86M
EPS (ttm) 0.35
PE Ratio 75.42
Forward PE 25.78
Dividend 0.08 (0.30%)
Ex-Dividend Date Jun 27, 2024
Volume 12,572
Average Volume 60,871
Open 26.65
Previous Close 26.70
Day's Range 26.10 - 26.65
52-Week Range 14.70 - 32.90
Beta 0.78
RSI 50.47
Earnings Date Apr 16, 2025

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o. [Read more]

Sector Healthcare
Founded 2002
Employees 515
Stock Exchange Warsaw Stock Exchange
Ticker Symbol CLN
Full Company Profile

Financial Performance

In 2023, Celon Pharma's revenue was 213.92 million, an increase of 10.33% compared to the previous year's 193.89 million. Losses were -28.12 million, -28.40% less than in 2022.

Financial Statements

News

Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease

Statistically significant improvement in primary endpoint (UDysRS total scale) at Week 4 and positive benefit in the key secondary endpoint (UDysRS objective subscale), beginning at Day 7 Favorable to...

4 weeks ago - Benzinga